Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01244490 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

338

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Extended-release Guanfacine Hydrochloride
DRUG: Atomoxetine Hydrochloride
DRUG: Placebo Comparator

Sponsor

Shire